Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Dysregulated immunologic landscape of the early host response in melioidosis
Patpong Rongkard, Lu Xia, Barbara Kronsteiner, Thatcha Yimthin, Rungnapa Phunpang, Adul Dulsuk, Viriya Hantrakun, Gumphol Wongsuvan, Parinya Chamnan, Lara Lovelace-Macon, Emanuele Marchi, Nicholas P.J. Day, Ali Shojaie, Direk Limmathurotsakul, Narisara Chantratita, Paul Klenerman, Susanna J. Dunachie, T. Eoin West, Sina A. Gharib
Patpong Rongkard, Lu Xia, Barbara Kronsteiner, Thatcha Yimthin, Rungnapa Phunpang, Adul Dulsuk, Viriya Hantrakun, Gumphol Wongsuvan, Parinya Chamnan, Lara Lovelace-Macon, Emanuele Marchi, Nicholas P.J. Day, Ali Shojaie, Direk Limmathurotsakul, Narisara Chantratita, Paul Klenerman, Susanna J. Dunachie, T. Eoin West, Sina A. Gharib
View: Text | PDF
Research Article Immunology Infectious disease

Dysregulated immunologic landscape of the early host response in melioidosis

  • Text
  • PDF
Abstract

Melioidosis, a neglected tropical infection caused by Burkholderia pseudomallei, commonly presents as pneumonia or sepsis with mortality rates up to 50% despite appropriate treatment. A better understanding of the early host immune response to melioidosis may lead to new therapeutic interventions and prognostication strategies to reduce disease burden. Whole blood transcriptomic signatures in 164 patients with melioidosis and in 70 patients with other infections hospitalized in northeastern Thailand enrolled within 24 hours following hospital admission were studied. Key findings were validated in an independent melioidosis cohort. Melioidosis was characterized by upregulation of interferon (IFN) signaling responses compared with other infections. Mortality in melioidosis was associated with excessive inflammation, enrichment of type 2 immune responses, and a dramatic decrease in T cell–mediated immunity compared with survivors. We identified and independently confirmed a 5-gene predictive set classifying fatal melioidosis (validation cohort area under the receiver operating characteristic curve 0.83; 95% CI, 0.67–0.99). This study highlights the intricate balance between innate and adaptive immunity during fatal melioidosis and can inform future precision medicine strategies for targeted therapies and prognostication in this severe infection.

Authors

Patpong Rongkard, Lu Xia, Barbara Kronsteiner, Thatcha Yimthin, Rungnapa Phunpang, Adul Dulsuk, Viriya Hantrakun, Gumphol Wongsuvan, Parinya Chamnan, Lara Lovelace-Macon, Emanuele Marchi, Nicholas P.J. Day, Ali Shojaie, Direk Limmathurotsakul, Narisara Chantratita, Paul Klenerman, Susanna J. Dunachie, T. Eoin West, Sina A. Gharib

×

Figure 1

Differential gene expression and pathway analysis in patients with melioidosis and other infections in the Ubon-sepsis discovery cohort.

Options: View larger image (or click on image) Download as PowerPoint
Differential gene expression and pathway analysis in patients with melio...
(A) Principal component analysis (PCA) of the top 1,000 most variable genes in patients hospitalized with community-acquired infections and community control cohorts. Patients with infections are divided into melioidosis (melioidosis, magenta dots, n = 164), other Gram-negative infections (navy dots, n = 35), Gram-positive infection (cyan dots, n = 16), and negative bacterial culture (culture negative, coral dots, n = 19) groups. Uninfected nonhospitalized controls are divided into healthy controls (black dots, n = 25), and diabetic controls (dm control, gray dots, n = 25). Each ellipse represents 95% CI of bivariate t distribution. (B) Volcano plot of differentially expressed genes (DEGs) between patients with melioidosis and uninfected community controls. (C–E) Volcano plots of DEGs among melioidosis versus other Gram-negative infection groups (C), melioidosis versus Gram-positive infection groups (D), and melioidosis versus culture-negative patients (E). Red indicates upregulation and blue indicates downregulation of DEGs. Dotted lines define a cut-off of differentially expressed genes based on absolute log2 fold change ≥ 1 (x axis) and adjusted P < 0.05 (y axis). Selected DEGs are labeled. (F) Corresponding functional pathway analysis was performed among patients with melioidosis compared with patients hospitalized with other infections (other Gram negative: G[–]; Gram-positive: G[+]; culture negative: Culture[–]) based on Reactome gene sets. The top 10 overrepresented pathways are displayed. Overrepresentation analysis was performed on prefiltered upregulated DEGs based on a cut-off of absolute log2 fold change ≥ 1 and adjusted P < 0.05 derived from C–E. The gradient color bar corresponds to the adjusted P value. The size of each term is indicated by gene counts.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts